TABLE 3 Findings that Distinguish Benign Spindle Cell Tumors of Bladder from Sarcoma
Tumor type | Clinical Findings | Pathology | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Mean Age | Antecedent Instrumentation | Mean ± SD Tumor Size (cm) | Muscularis Invasion (% of Cases) | Necrosis | Small Blood Vessels | Cytologic Atypia | Mitotic Rate/10 hpf | p53 Nuclear Immunostain | Inflammatory Cells/hpf, Type | |
Inflammatory pseudotumor | 38 | No | 4.4 ± 0.7 | 77% | None | Prominent, several per hpf | Minimal | 0 –2 | Weak or absent | 153, chronic (many plasma cells); eosinophils in 1 case |
Postoperative spindle cell nodule | 65 | Surgery, up to 6 yr prior | 1.5 ± 0.5 | 60% | May be present superficially | Prominent, several per hpf | Minimal | 0 –15 | Weak or absent usuallya | 140, chronic; less with post-op. time; prominent eosinophils in 3 cases |
Low-grade sarcoma | 52 | No | 3.2 ± 0.9 | 100% | Present at tumor-detrusor muscle bundle interface | Fewer | Moderate | 1 –16 | Moderate to strong | 24, acute more than chronic |
High-grade sarcoma | 50 | No | 4.6 ± 0.8 | nd | Present at tumor-detrusor muscle bundle interface | Fewer | Severe | 1 –3 | Moderate to strong | 101, acute more than chronic |
